Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
一项评估伊布替尼联合氟达拉滨、环磷酰胺和利妥昔单抗作为慢性淋巴细胞白血病一线治疗方案的II期研究的五年随访结果
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2023011574
Ahn, Inhye E; Brander, Danielle M; Ren, Yue; Zhou, Yinglu; Tyekucheva, Svitlana; Walker, Heather A; Black, Robert; Montegaard, Josie; Alencar, Alvaro; Shune, Leyla; Omaira, Mohammad; Jacobson, Caron A; Armand, Philippe; Ng, Samuel Y; Crombie, Jennifer; Fisher, David C; LaCasce, Ann S; Arnason, Jon; Hochberg, Ephraim P; Takvorian, Ronald W; Abramson, Jeremy S; Brown, Jennifer R; Davids, Matthew S